Expedeon AG signs supply and license agreement with Quanterix Corporation for access to proprietary immunoassay technologyNovember 7, 18
Expedeon’s proprietary immunoassay technology to be incorporated into
Quanterix’ Simoa Planar Immunoassay products
Heidelberg, Germany and Cambridge, UK, 07 November 2018 – Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) today announced a supply and license agreement with United States based Life Sciences company, Quanterix Corporation. The agreement provides Quanterix access to Expedeon’s breadth of immunoassay technologies for application to their ultrasensitive Simoa Immunoassay offerings.
The agreement with Quanterix will provide non-exclusive access to Expedeon’s CaptSure™ immunoassay technology for single target analysis (singleplex), as well as the rapid Lightning-Link® conjugation technology for antibody labelling.
Dr Heikki Lanckreit, CEO and CSO of Expedeon, said: “This agreement brings together two companies that are pushing new boundaries with their respective technologies. Expedeon is a leader in the development of immunoassay technologies that speed up life science research. Combining our technologies with those of Quanterix will provide the industry with unmatched new capabilities for protein discovery. We are extremely excited about this new venture, and look forward to examining further opportunities with Quanterix as the partnership expands.”
Unlike conventional immunoassay technologies, the CaptSure™ system provides a universal base onto which antibodies can be immobilised. In conjunction with Lightning-Link® technology it provides for a robust, reliable and faster immunoassay system, with the ability to deploy assay content across different test platforms.
“We are pleased to be able to incorporate Expedeon technologies in our newest product offerings, providing additional flexibility and performance to researchers utilizing our Simoa technology to measure digital biomarkers and fuel new discoveries,” said Kevin Hrusovsky, Quanterix’ CEO, President and Chairman.
This entry was posted in News from Zyme and the companies we work with. Bookmark the permalink.